A solubilized alpha-fucosyltransferase activity has been isolated from a bovine spleen Golgi-rich membrane fraction. The enzyme transfers fucose from GDP-beta-L-fucose to a blood group B-active pentaglycosylceramide acceptor (Gal(alpha 1-3)Gal(beta 1-4)GlcNAc(beta 1-3)Gal(beta 1-4)Glc-ceramide) isolated from rabbit erythrocytes. Treatment of the membranes with 0.2% (final concentration) sodium taurodeoxycholate detergent produced maximal recovery (90%) of activity. A cationic detergent, G-3634-A, is required for optimal activity and the enzyme does not require addition of exogenous metal ion for activation. The purified 14C-labeled product of the reaction migrated with human blood group B-active hexaglycosylceramide on Silica Gel G thin layer plates. After treatment with fig alpha-galactosidase, the radioactive pentaglycosylceramide migrated with human H-active glycosphingolipid. The 14C-labeled product inhibited the hemagglutination reaction of B-type erythrocytes with Bandeiraea simplicifolia lectin and anti-B serum and formed a precipitin line with Euonymus europeus lectin. Treatment of the 14C-labeled product with alpha-fucosidase (Venus mercenaria) or weak acid at 100 degrees C for 2 h released 80-90% of the bound radioactive fucose.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Six-month Rituximab-Lenalidomide regimen in advanced untreated Follicular Lymphoma: SAKK 35/10 Trial 10-year Update.
Blood Adv
January 2025
Ente Ospedaliero Cantonale, Switzerland.
The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/10 randomized phase-2 trial (NCT0137605) to compare rituximab (R) alone versus R plus lenalidomide (L) as initial treatment for follicular lymphoma (FL). Patients with grade 1-3a FL, requiring systemic therapy, were randomized to either R (n=77; 375 mg/m2 IV x 1, weeks 1-4) or RL (n=77; R on the same schedule and L at 15 mg daily continuously). Responders (evaluated at 10 weeks) repeated R during weeks 12-15 with or without L (for a total of 18 weeks).
View Article and Find Full Text PDFSolitary Plasmacytoma: Single institution experience and systematic review and meta-analysis of clinical outcomes.
Blood Adv
January 2025
Mayo Clinic, Rochester, Minnesota, United States.
In this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then expanded our investigation through a systematic review and meta-analysis of 62 studies, encompassing 3,487 patients from the years 1960 to 2022. Our findings reveal that patients with up to 10% clonal plasma cells in their bone marrow (BM), denoted as plasmacytoma +, had a significantly reduced median disease-free survival (DFS) of 15.7 months vs.
View Article and Find Full Text PDFMRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial.
Blood
January 2025
Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); University of Cologne, Faculty of Medicine and University Hos, Cologne, Germany.
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total, 42 patients were enrolled and two patients with ≤2 induction cycles were excluded from the analysis population per protocol. Patients had a median of one prior therapy (range 1-5), 18 patients (45%) had already received a BTK inhibitor (BTKi), seven patients (17.
View Article and Find Full Text PDFOral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources.
JCO Glob Oncol
January 2025
Genitourinary Medical Oncology Service, Instituto do Câncer do Estado de São Paulo (ICESP), University of São Paulo, São Paulo, Brazil.
Purpose: Prior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underutilized in routine clinical practice given the lack of survival benefit and the emergence of more effective treatments.
Methods: We retrospectively reviewed our institutional database to identify patients with mCRPC treated with cyclophosphamide.
Patient outcomes and health care resource utilization in acute pancreatitis-related central nervous system complications: insights from a national cohort study.
J Int Med Res
January 2025
Department of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, United States.
Objectives: Central nervous system complications of acute pancreatitis (AP) can result in cerebral edema (CE). We assessed the risk of serious outcomes and health care features associated with CE in patients hospitalized with AP.
Methods: We conducted a retrospective cohort study using the National Inpatient Sample database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!